Last reviewed · How we verify

NCT07506161

Radiofrequency Ablation Treatment of Low-Risk Papillary Thyroid Carcinomas

Completed Last updated 1 April 2026
What this trial tests

trial testing Radiofrequency ablation alone in Papillary Thyroid Microcarcinoma in 27 participants. Completed in 31 December 2025.

Timeline
9 September 2021
Primary endpoint
31 December 2025
31 December 2025

Quick facts

Lead sponsorPremier G Med Cardio Kft
StatusCompleted
Study typeOBSERVATIONAL
Enrollment27
Start date9 September 2021
Primary completion31 December 2025
Estimated completion31 December 2025
Sites1 location across Hungary

Drugs / interventions tested

Conditions studied

Sponsor

Premier G Med Cardio Kft

Who can join

18 and older, any sex, with Papillary Thyroid Microcarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Researchers in this study aim to prove the safety and efficacy of radiofrequency ablation in the treatment of a carefully selected low-risk papillary thyroid microcarcinoma patient group.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Radiofrequency ablation alone

Trials testing the same drug.

Other recruiting trials for Papillary Thyroid Microcarcinoma

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07506161.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing